Professor Jenner is a director of the Neurodegenerative Diseases Research Centre and the National Parkinson’s Foundation Centre of Excellence in the UK. He leads a 20-strong internationally-recognized research team that focus on the cause, treatment and cure of Parkinson's disease. In particular, he has contributed significantly to the concept of oxidative stress as a cause of the progression of nigral cell death in Parkinson's disease. In addition, he has been responsible for developing novel compounds for the treatment of Parkinson's disease and the avoidance of dyskinesia through the use of experimental models of the illness. Until 2004, Professor Jenner was head of the division of pharmacology & therapeutics in the Guy's, King's & St Thomas' School of Biomedical Sciences at King's College London. He has published more than 400 papers in peer reviewed journals, written in excess of 100 review articles and book chapters and written or edited numerous monographs. He is a member of the Medical Advisory Panel of the Parkinson's disease Society of the United Kingdom and Chief Scientific Officer of Proximagen, a biotechnology company spun out of King’s College London.